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Crohn’s disease (CD) is an immune-mediated intestinal illness that significantly compro-
mises health in many developed countries. Although definitive causes remain elusive, 
the required contribution of microbes in the progression of disease has become an 
accepted concept. Known CD risk factors, such as antibiotic use and acute infectious 
gastroenteritis, may impact the gut. This concept is now being explored with a view 
toward understanding the beneficial and unfavorable microbes that may be altered in 
numbers during such external insults. A comprehensive understanding of the microbial 
component to CD could be useful clinically as future therapies may focus on preventing 
risk exposures on susceptible individuals, eliminating harmful microbes, or restoring a 
protective gut microbiome. Here, we examine how acute infectious gastroenteritis and 
antibiotic exposure may impact the gut microbiota in the context of inflammation in CD.
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iNTRODUCTiON
Crohn’s disease (CD) is part of the inflammatory bowel disease spectrum that can affect any portion 
of the gastrointestinal tract. CD is becoming increasingly common in many high-income nations, 
particularly among the pediatric population (1). Due to its high prevalence and chronic disease 
course, CD imposes significant directs costs on the health care system, along with a high attendant 
societal cost (2). Since the classification of CD in the 1950s, significant investments have been made 
in understanding the root causes of the disease, as well as in new treatments to induce remission 
that target mainly the aberrant inflammatory response underlying the disease course. Although 
genetics are known to play an important role in CD (3, 4), penetrance is low for any one genetic 
risk allele. Furthermore, the sharp rise in CD in many countries over the past 40 years indicates that 
genetics alone does not fully explain the etiology of disease, but rather that environmental exposures 
may be antecedent to disease initiation and progression in a genetically susceptible population (5). 
Understanding the nature and origins of such environmental risk factors is of paramount importance 
in curbing the rise of CD worldwide.
Clinical and animal studies have provided robust data indicating that intestinal microorganisms, 
both luminal and tissue-associated, play an important role in CD pathogenesis (5–9). For example, 
a pathogenic role for luminal bacteria is consistent with the beneficial effects of experimental fecal 
stream diversion following ileocolonic resection (10) and levels of epithelial-adherent bacteria have 
been found to correlate clinically with CD severity (11, 12). Environmental exposures, such as infec-
tious agents or use of certain xenobiotics, can create intestinal vulnerabilities, rendering one more 
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susceptible to the functional and microbial changes associated 
with CD. In this review, we briefly summarize the microbial 
composition changes that have been described in CD patients, 
and discuss two CD risk factors – acute infectious gastroenteritis 
and exposure to antimicrobial agents – that are known to induce 
pervasive changes to the microbial composition in the gut. The 
potential for dysbiosis-inducing external insults such as these to 
select for the expansion of pathobiont-like bacteria that affect the 
inflammatory tone of the gut is discussed.
MiCROBiAL DYSBiOSiS iN CROHN’S 
DiSeASe
The advent of high-throughput sequencing has allowed research-
ers to investigate the gut microbiome in health and disease states, 
which was previously difficult to study due to the immense 
quantity and diversity of species present as well as the difficulty 
in getting broad representation of the intestinal community by 
culturing methods (13). Several high-throughput methods have 
been developed over the past decade that have allowed research-
ers to identify intestinal bacteria based on genetic signatures. One 
method involves using fluorescence in situ hybridization (FISH) 
probes designed to label certain groups of bacteria. These labeled 
bacteria can then be quantified using flow cytometry (FCM-FISH) 
(14). This method has the advantage of being relatively simple and 
inexpensive; however, the FCM-FISH method has relatively poor 
resolution and can only identify broad changes in bacterial groups. 
High-throughput sequencing has set a new benchmark, allowing 
researchers to analyze the population structure of complex micro-
bial communities (15). In this regard, 16s rRNA is a useful genetic 
marker as it is universally present among all bacteria. It contains 
both variable regions useful for genomic classification and con-
served regions that can be used to design universal primers. The 
choice of primers is extremely important, as even “universal” 
primers may poorly amplify some bacterial families. Although 
sequencing larger segments of the 16s rRNA region provides 
more resolution, most high-throughput sequencing technologies 
are limited to sequencing several hundred base pairs. For this 
reason, most studies analyze only one or several variable regions 
of the 16s rRNA gene. Nonetheless, even short reads of variable 
regions around 100 bases are usually sufficient to differentiate 
many microbes to the genus level, although using different vari-
able regions can lead to different results (16). When comparing the 
results of 16s rRNA sequencing, it is important to consider differ-
ences in primer choice and the length of DNA sequenced from 
each fragment. Additionally, differences in data clean up as well as 
data analysis can lead to additional variability. For example, differ-
ent analysis procedures between groups can result in considerable 
discrepancies in data generation and interpretation that should 
be taken into consideration when comparing observations from 
different publications. Nevertheless, some themes are emerging 
from the literature, which are discussed below.
The human microbiome is composed primarily of anaerobes 
within the bacterial phyla Firmicutes and Bacteriodetes. One of 
the first studies to investigate the CD microbiome examined 
fecal bacteria from six healthy individuals and six CD patients 
FiGURe 1 | Phylogenetic tree of bacterial groups associated with increased or decreased abundance in the gut microbiome of Crohn’s disease 
patients. In cases were bacterial groups have been associated both increases and decreases, studies showing increased abundance are indicated with “↑” and 
studies showing decreased abundance are indicated with “↓.” Numbers indicate references as follows; 1, Frank et al. (21); 2, Gevers et al. (27); 3, Hansen et al. (31); 
4, Morgan et al. (22); 5, Sokol et al. (20); 6, Manichanh et al. (17); 7, Sokol et al. (32); 8, Sokol et al. (33). Tree topology was created using phyloT (http://phylot.
biobyte.de/) and the figure was made using ITOL (http://itol.embl.de/).
using both 16s rRNA sequencing and FCM-FISH (17). All CD 
patients were in remission, had no exposure to antibiotics for at 
least 3 months, and had previous ileal involvement in the disease 
course. In this study, CD patients had much lower microbial 
diversity than the control group, with 88 ribotypes represented in 
healthy subjects compared to only 54 in CD patients. This change 
was largely due to decreased diversity in the Firmicutes phylum, 
in particular, the Clostridium leptum group. C. leptum are known 
to produce butyrate, a short chain fatty acid (SCFA) and energy 
source for the intestinal epithelium. Butyrate has also been shown 
to down regulate pro-inflammatory mRNA within enterocytes 
and to acidify the intestinal lumen that is thought to inhibit 
certain pathogens such as Salmonella and Escherichia coli (18, 
19). A similarly designed study using FCM-FISH analyzed fecal 
samples from 14 CD patients and 13 healthy controls that had 
not received sulfasalazine, antibiotics, or laxatives in the month 
prior to analysis (20). Using FISH with group-specific probes the 
study also found that C. leptum was significantly decreased in the 
CD group.
A larger study examined intestinal biopsy samples rather 
than fecal samples, from CD and UC patients and healthy con-
trols (n =  190) using 16s rRNA sequencing (21). Bacteroidetes 
and Lachnospiraceae groups were greatly decreased in these 
subjects, whereas Actinobacteria and Proteobacteria groups were 
increased. Another study investigated both fecal and mucosal 
samples from healthy (n = 27), CD (n = 121), and UC patients 
(n = 75) utilizing 16s rRNA sequencing of V3–V5 regions (22). 
Roseburia, Phascolarctobacterium, and Ruminococcaceae were all 
reduced in CD patients. These microbial groups are also impor-
tant producers of SCFA. In ileal CD patients, Ruminococcaceae 
and Faecalibacterium groups were particularly reduced while 
Escherichia/Shigella species were enriched, a finding that has been 
reproduced in several studies. Interestingly, the use of 5-ASA 
was strongly correlated with a decrease in Escherichia/Shigella. 
Various genera within Clostriales order were decreased in 
patients treated with antibiotics, possibly due to their sensitivity 
to ciprofloxacin/metronidazole often used in CD treatment. The 
genes involved in several major metabolic pathways have been 
well characterized in model bacteria. Since many of the genome 
of gut microbes have been sequenced, it is possible to predict if a 
microbe lacks a particular classical pathway based on an absence 
of conservation to known genes typically involved in that pathway. 
Overall, microbes from IBD patients had decreased pathways for 
amino acid synthesis coupled with increased amino acid uptake 
pathways. There were also increased levels of carbohydrate and 
lipid uptake and metabolism pathways, particularly in ileal CD. 
Many of these changes may aid in the metabolism of mucin, 
which is often overproduced during intestinal inflammation. 
The reduction in amino acid synthesis resembles phenotypes 
elicited by murine pathobionts known as segmented filamentous 
bacteria (23, 24). The microbiome showed increased glutathione 
uptake, which may be important for surviving oxidative stress 
from inflammation (25). Finally, the ileal CD metagenome was 
enriched in bacterial secretion systems, in particular, the type II 
secretion system that is often used in the export of toxins (26).
Another recent study analyzed the treatment-naïve micro-
biome of pediatric CD patients (n = 447) and healthy controls 
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(n  =  221) using tissue biopsies and feces and sequencing 
the 16s rRNA V4 region (27). When comparing intestinal 
biopsy samples from healthy individuals to CD patients, the 
Bacteroidales and several species within the C. leptum groups 
had lower abundance in pediatric CD patients in accordance 
with previous studies. Several bacterial families that were found 
to be more abundant were Enterobacteriaceae, Pasteurellaceae, 
Veillonellaceae, Neisseriaceae, and Fusobacteriaceae. The use of 
antibiotics in patients already diagnosed with CD is controver-
sial (28, 29). However, in this study, a subset of CD patients had 
been treated with antibiotics providing for a separate analysis. 
When this group was analyzed separately, it was found that 
antibiotic exposure amplified the microbial dysbiosis associ-
ated with CD. Importantly, in new onset patients, the micro-
bial dysbiosis was poorly reflected in the stool compared to 
tissue biopsy samples, which might suggest that the bacterial 
community of pathogenic significance in the disease is tissue 
associated.
Overall, these studies consistently show that CD is associ-
ated with decreased abundance and diversity of the Firmicutes 
phylum with an increased abundance in the Proteobacteria 
phylum (Figure 1). Tissue samples appear to be more indicative 
of dysbiosis compared to fecal samples at least in early disease. 
Although Firmicutes appear decreased in overall abundance in 
CD, some specific members of the Firmicutes are conversely 
increased. These studies occasionally differ on the particular 
groups of bacteria that are elevated or reduced in CD patients. 
These differences may be due to differences in sample type 
(luminal vs. tissue) as well as differences in patient populations 
(patients with active disease vs. remission, treated patients vs. 
treatment naïve), or in method of analysis. How these shifts 
in microbial ecology contribute to the pathophysiology of CD 
remains an active area of research. A recent study using a murine 
model of CD demonstrated that bacteria gut dysbiosis played a 
causal role in intestinal inflammation (30). Several mechanisms 
may explain why dysbiosis is associated with CD. It is possible 
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probes designed to label certain groups of bacteria. These labeled 
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inexpensive; however, the FCM-FISH method has relatively poor 
resolution and can only identify broad changes in bacterial groups. 
High-throughput sequencing has set a new benchmark, allowing 
researchers to analyze the population structure of complex micro-
bial communities (15). In this regard, 16s rRNA is a useful genetic 
marker as it is universally present among all bacteria. It contains 
both variable regions useful for genomic classification and con-
served regions that can be used to design universal primers. The 
choice of primers is extremely important, as even “universal” 
primers may poorly amplify some bacterial families. Although 
sequencing larger segments of the 16s rRNA region provides 
more resolution, most high-throughput sequencing technologies 
are limited to sequencing several hundred base pairs. For this 
reason, most studies analyze only one or several variable regions 
of the 16s rRNA gene. Nonetheless, even short reads of variable 
regions around 100 bases are usually sufficient to differentiate 
many microbes to the genus level, although using different vari-
able regions can lead to different results (16). When comparing the 
results of 16s rRNA sequencing, it is important to consider differ-
ences in primer choice and the length of DNA sequenced from 
each fragment. Additionally, differences in data clean up as well as 
data analysis can lead to additional variability. For example, differ-
ent analysis procedures between groups can result in considerable 
discrepancies in data generation and interpretation that should 
be taken into consideration when comparing observations from 
different publications. Nevertheless, some themes are emerging 
from the literature, which are discussed below.
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FiGURe 1 | Phylogenetic tree of bacterial groups associated with increased or decreased abundance in the gut microbiome of Crohn’s disease 
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ANTiBiOTiCS AS A RiSK FACTOR FOR CD
Antibiotics are commonly prescribed for a wide range of ill-
ness and are occasionally used in the treatment of CD (45). 
Antibiotics have long been known to have negative impacts on 
commensal microbes and are known to be an important risk 
factor for gastrointestinal illnesses, such as Clostridium difficile 
infection (46, 47). Several epidemiological studies have linked 
exposure to antibiotics with CD, which are summarized in 
Table 2. A case–control study in Canada compared antibiotic use 
in individuals with incident IBD diagnosis and non-IBD controls 
and found that patients diagnosed with IBD were more likely to 
have been prescribed antibiotics in the preceding 5 years before 
diagnosis (48). Of interest, there was a dose-dependent relation-
ship between the number of antibiotics dispensed and the risk of 
subsequent IBD diagnosis. The risk of subsequent IBD diagnosis 
was highest 2 years after antibiotics and diminished over time. 
Nearly all antibiotics included in this study, with the exception 
of clindamycin, were associated with an increased risk of IBD 
diagnosis. Interestingly, metronidazole had the highest risk (AOR 
2.86 [2.24–3.65]) followed by quinolones (AOR 1.45 [1.27–1.64]). 
Both of these antibiotics are also used as treatments for CD.
A case–control study using data from the UK examined 
patient medical history at least 5 years prior to diagnosis of CD 
(49). Again, patients who were later diagnosed with CD were 
more likely to have taken antibiotics (OR 1.32 [1.05–1.65]). 
When individual antibiotics were examined, only metronidazole 
and tinidazole (OR 1.71 [1.05–2.76]) and tetracylines (OR 1.33 
[1.01–1.77]) were associated with subsequent CD. This study did 
not find a dose-dependent relationship between the numbers of 
antibiotics dispensed and overall CD risk.
A cohort study from the UK examined the association 
between oral tetracycline for the treatment acne in adults and 
adolescents and subsequent IBD diagnosis (50). Once again, 
there was an association between tetracycline use and IBD (HR 
1.39 [1.02–1.90]) and a stronger association with CD in particular 
(HR 1.62 [1.04–2.53]). Furthermore, the risk of CD varied based 
on the type of antibiotic, with minocycline conferring the lowest 
TABLe 1 | epidemiological studies associating infectious gastroenteritis and Crohn’s disease.
Study Type Location Population size Type of association Risk [95% Ci]
Garcia Rodriguez et al. (36) Retrospective cohort United Kingdom IGE: 43,013 Cont: 50,000 Overall HR 6.6 [1.9, 22.4]
Porter et al. (37) Case–control United States CD: 1,037 Cont: 11,646 Overall OR 1.54 [1.1, 2.04]
Gradel et al. (38) Case–control Denmark IGE: 13,148 Cont: 26,216 Overall HR 3.0 [1.7, 5.3]
IGE, infectious gastroenteritis; HR, hazard ratio; OR, odds ratio.
that dysbiosis contributes to CD because the loss of SCFA pro-
ducing bacteria has multiple impacts on the gut environment, 
including impaired survival of enterocytes, increased production 
of inflammatory cytokines, and decreased suppression of poten-
tially pathogenic Proteobacteria. It is also possible that dysbiosis 
is caused by the intestinal inflammation in CD. Bacterial species 
from Proteobacteria are facultative anaerobes that tend to have 
a higher resistance to reactive-oxygen species produced during 
inflammation, possibly giving them a selective advantage over 
the predominantly obligate anaerobes from Firmicutes and 
Bacteroidetes. These mechanisms are not mutually exclusive, and 
it is likely that microbial dysbiosis both contributes to and results 
from the intestinal inflammation seen in CD.
One member of the Firmicutes that has received much atten-
tion in the context of CD is Faecalibacterium prausnitzii, a major 
member of the C. leptum group of Firmicutes that is decreased 
in CD patients (32). In particular, a higher abundance of F. 
prausnitzii was associated with a higher rate of remission fol-
lowing resection surgery (33). In vitro analysis showed that this 
bacterium was capable of inhibiting NFκB and the secretion of 
pro-inflammatory cytokines, as well as stimulating the release of 
anti-inflammatory cytokines, such as IL-10. In vivo studies using 
dinitrobenzene sulfonic acid (DNBS) (34) and trinitrobenzene-
sulfonic acid (TNBS) (33)-induced colitis models showed that F. 
prausnitzii and its culture supernatant were capable of attenuating 
inflammation when introduced both orally and into the peritoneal 
cavity. An intriguing recent study has identified a protein secreted 
by F. prausnitzii that may explain its anti-inflammatory properties 
(35). However, the exact role of F. prausnitzii in the pathogenesis 
of CD has yet to be elucidated. Two studies of pediatric patients 
with newly diagnosed, untreated CD conflictingly showed 
increased (31) and decreased (27) levels of in F. prausnitzii com-
pared to healthy controls. It is possible that the decreased levels of 
F. prausnitzii are a characteristic of adult CD but not pediatric CD. 
It is also possible that F. prausnitzii is lost due to medications used 
to treat CD such as antibiotics rather than having a direct link to 
disease expression. Additional research is needed to determine 
how levels of F. prausnitzii might dictate the fine balance between 
health and disease in the gut.
iNFeCTiOUS GASTROeNTeRiTiS AS 
A RiSK FACTOR FOR CD
Amply powered clinical studies show that acute infectious 
gastroenteritis caused by enteric pathogens (including 
Salmonella and pathogenic E. coli) increases the short- and 
long-term risk of developing CD (36–38) (Table  1). In one 
study, Garcia-Rodríguez et al. compared a cohort of individuals 
with acute gastroenteritis (N = 43,013) with matched controls 
without documented gastroenteritis (N  =  50,000), excluding 
individuals with previous IBD diagnosis (36). Over a mean 
follow-up period of 3.5  years, there was an increased risk of 
developing IBD after a single episode of acute gastroenteritis 
(HR 2.4 [1.7–3.3]). The association was stronger with CD com-
pared to ulcerative colitis (UC), particularly in the first year after 
gastroenteritis (HR 6.6 [1.9–22.4]). A second case–control study 
by Porter et al. compared individuals diagnosed with CD with 
healthy controls (37). The study examined previous diagnoses 
of infectious gastroenteritis in both groups. Patients with IBD 
were more likely to have had a previous diagnosis of infectious 
gastroenteritis (AOR 1.40 [1.19–1.66]). Once again, the risk was 
higher for CD (AOR 1.54 [1.17–2.04]) than for UC (AOR 1.36 
[1.08–1.72]). Finally, a retrospective study compared cohorts of 
healthy individuals in Denmark to those diagnosed with acute 
gastroenteritis caused by either Salmonella or Campylobacter, 
tracking subsequent IBD diagnoses over the following 15 years 
(38). Overall, the gastroenteritis group had an increased risk of 
subsequent IBD diagnosis over the entire 15-year period (HR 
2.9 [2.2–3.9]), with the greatest risk occurring in the first year 
following an episode of acute gastroenteritis.
Due to the observational nature of these studies, it is difficult 
to determine whether infection predisposes individuals to CD 
or if individuals with a susceptibility CD are more susceptible 
to infection. It is possible that low-grade inflammation in 
prodromal CD may lower the colonization resistance to enteric 
pathogens, a phenomenon has been demonstrated in murine 
models (39). Several studies have shown that infectious gastro-
enteritis is associated with microbial dysbiosis, albeit transiently 
(40, 41), that might underlie the microbial triggers of chronic 
disease. Though the mechanisms are currently unknown, the 
long-term risk of developing CD following acute infectious 
gastroenteritis might suggest that resident gut microbes could 
perpetuate inflammatory reactions in the post-infectious period. 
One central hypothesis is that exposure to infectious pathogens 
creates an environment favorable to colonization by other pro-
inflammatory bacteria. These may be existing members of the 
microbiota typically restricted by microbial and host processes, 
or they may be acquired de novo through vulnerabilities created 
by the disruption of the resident microbiota during gastroenteri-
tis. For example, human (42) and animal studies (43, 44) indicate 
that inflammation during gastroenteritis selectively disrupts the 
resident intestinal microbiota in favor of Enterobacteriacea, 
such as E. coli. Whether such disruptions have long-term conse-
quences on the host in the post-infectious period has not been 
rigorously studied.
TABLe 2 | epidemiological studies associating antibiotic treatment with subsequent CD diagnosis.
Study Type Location Population size  
(CD:control or  
cohort size)
Type of association Risk [95% Ci]
Card et al. (49) Adult United Kingdom 587:1460 2–5 years before CD diagnosis OR 1.32 [1.05, 1.65]
Case–control
Margolis et al. (50) Adult United Kingdom 94,487 Overall HR 1.62 [1.04, 2.53]
Retrospective cohort
Shaw et al. (48) Adult Canada 1025:22,346 2–5 years before CD diagnosis AOR 1.29 [1.18, 1.40]
Case–control
Hildebrand et al. (53) Pediatric Sweden 1098:6550 Pneumonia <5 years old OR 3.56 [1.79, 7.08]
Case–control
Hviid et al. (51) Pediatric Denmark 577:627 Overall RR 3.41 [1.45, 8.02]
Retrospective cohort
Virta et al. (52) Pediatric Finland 233:2380 2 years before CD diagnosis AOR 1.87 [1.37, 2.56]
Case–control
OR, odds ratio; HR, hazard ratio; AOR, adjusted odds ratio; RR, relative risk.
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risk (HR 1.28 [0.72–2.29]) followed by tetracycline (HR 1.61 
[1.00–2.63]) and finally doxycycline (HR 2.25 [1.27–4.00]).
Several studies in pediatric patients have shown similar results. 
A study in Denmark followed all singleton children born between 
1995 and 2003 (51) and tracked antibiotic prescriptions and IBD 
diagnoses. CD, but not UC, was associated with previous antibiotic 
prescriptions (RR 3.41 [1.45–8.0]). This relationship was dose 
dependent, with the highest risk being among children prescribed 
≥7 antibiotics (RR 7.32 [2.14–24.9]). Interestingly, the risk of 
diagnosis was highest within 3 months of antibiotic exposure (RR 
4.43 [1.88–10.44]). Penicillin V and extended spectrum penicillins 
conferred the highest risk (RR 2.92 [1.22–6.97] and RR 3.13 [1.33–
7.40], respectively). Another study from Finland similarly found an 
association between antibiotic use 2 years preceding CD (AOR 1.87 
[1.37–2.56]), but not UC, diagnosis (52). Cephalosporin antibiotics 
were associated with the highest risk. Finally, a Swedish study which 
used childhood infections as a proxy for antibiotic treatment found 
a position association between pneumonia, diagnosed at <5 years 
old, and subsequent CD (OR 3.56 [1.79–7.08]) (53).
These studies have provided evidence for a correlation between 
antibiotic use and subsequent diagnosis of CD; however, most 
of the studies do not agree on a specific class of antibiotic that 
confers the highest risk, which may relate to differences in patient 
populations or prescribing practices. Due to the observational 
nature of these studies, it is difficult to show causality between 
antibiotics and CD and it remains possible that the phenotype 
that makes one susceptible to CD may also make one susceptible 
to infections requiring antibiotics. Conversely, among patients 
already diagnosed CD, the use of antibiotics is associated with a 
reduced chance of flaring (54). Relatively short courses of antibi-
otics are known to lead to dramatic shifts and loss of diversity on 
the gut microbiome, which can persist for years (55). It is possible 
that antibiotic exposure may trigger an unfavorable microbial 
community structure that increases the potential for long-term 
dysbiosis and risk of CD in susceptible individuals. Microbiome 
comparison between CD patients with and without exposure to 
antibiotics supports this claim, showing that antibiotics magnify 
the dysbiosis signature associated with CD (27). Nonetheless, 
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robust experimental evidence is needed to clarify the impact of 
antibiotic use on host susceptibility to disease.
TiSSUe-ASSOCiATeD BACTeRiA ARe 
iNCReASeD iN CROHN’S DiSeASe
Inflammation in CD can involve both the small and large bowel 
and is accompanied by changes in the microbial composition and 
distribution at these sites (6, 13). Clinical observations are consist-
ent in finding increased numbers of bacteria associated with the 
intestinal epithelium in Crohn’s patients (5, 12, 22). The intestinal 
mucosa, made up of the epithelium and underlying lamina propria, 
is a site rich in immune cell populations that protect the integrity 
of the epithelial surface and direct the innate and adaptive immune 
responses. Since this site is consistently breached in CD, atten-
tion has focused on the relationship between the innate immune 
system and the microbiota (56), with a particular emphasis on the 
bacteria that penetrate into this normally aseptic site. Examination 
of the mucosa in ileal CD has been informative. It is here that the 
density of E. coli, enriched in virulence and secretion pathways, is 
elevated as determined by culture and molecular methods (11, 22, 
57). Use of bowel-specific aminosalicylates is associated with nor-
malization of this E. coli bloom in ileal disease (22, 58), suggesting 
that inflammation might somehow benefit certain bacteria that 
are associated with the mucosal surface. This finding is important 
clinically because the severity of ileal disease has been shown to 
correlate directly with the density of mucosa-associated E. coli (12). 
The implication of course is that reducing the burden of mucosa-
associated bacteria would have favorable outcomes on the disease 
course, possibly opening up new therapeutic avenues beyond 
immunosuppression. Together, these data support the general 
view that mucosa-associated E. coli are of pathogenic significance 
in the disease and that their abundance can be manipulated using 
pharmacologic treatments directed at host inflammation. These 
results stimulate many important and interesting questions. For 
example, they imply that the selective environment favoring E. 
coli expansion at the mucosal surface is inflammatory in nature. 
Although the exact source of this selection is not yet known, fruitful 
lines of investigation can be envisaged to uncover it. Furthermore, 
does the inflamed mucosa render a host more susceptible to de 
novo colonization by bacteria with pathobiont-like features, or is 
this expansion seeded from a resident population of opportunistic 
bacteria that exploit this favorable niche? Lastly, the genetically 
encoded bacterial adaptations needed for mucosal expansion 
in the inflamed gut are not known, but uncovering them would 
offer valuable insight into the evolutionary process that selects 
for such pathobionts. The upshot of this information would be 
new useful genetic markers for detecting pathobionts in hosts and 
other potential environmental reservoirs, and in identifying new 
potential targets for antimicrobial drug discovery.
ADHeReNT-iNvASive E. coli iN CROHN’S 
DiSeASe
Much experimental and observational data implicate infectious 
agents in the initiation and maintenance of chronic inflammation 
in the intestine (6). E. coli is a Gram-negative species in the intestine 
where it can have a positive effect on gut homeostasis. However, 
through acquisition of virulence factors, such as toxins, adhesins, 
and secretion systems, E. coli can develop pathogenic traits that 
participate in intestinal and extraintestinal disease processes (59). 
Work originating from the laboratory of Dr. Darfeuille-Michaud 
identified E. coli in ileal biopsies from patients with CD (57), 
which they called adherent-invasive E. coli (AIEC) to reflect their 
atypical ability to adhere to mucosal epithelial cells and invade 
and survive within human cells. These E. coli were found to lack 
known virulence factors typical of pathogenic E. coli, including 
type III secretion systems or phage-encoded toxins, suggesting 
that they were a newly described pathovar. A series of papers 
followed that detailed the intracellular lifestyle of AIEC and the 
inflammatory response by cultured cells to AIEC infection (60, 
61). AIEC are capable of replicating within macrophages and 
causing these cells to release high amounts of TNFα in vitro (62). It 
also appears possible that AIEC exploit cell phenotypes associated 
with genetic CD risk factors, such as defects in autophagy (63).
Several studies have now confirmed that AIEC are enriched in 
humans with CD, where they are six-times more likely to be iso-
lated from ileal and colonic samples compared to healthy controls 
and represent the dominant bacterial species present (57, 64, 65). 
A growing body of work has uncovered genetic and phenotypic 
diversity among AIEC isolated from adults (12, 65–67), children 
(68, 69), and companion animals (70) indicating that different 
host environments can select for the AIEC phenotype. Since 
AIEC can be isolated from seemingly healthy individuals (albeit 
much less frequently than in Crohn’s), this genetic diversity sug-
gests that interactions between AIEC and other CD risk factors 
might be needed to elicit disease in a subset of individuals.
In 2013, Small et  al. established a novel model for chronic 
AIEC infection in conventional mice (8), that over time, develop 
transmural inflammation and fibrosis in the small and large intes-
tine, the very hallmarks of CD. Importantly, this happens over 
timescales consistent with a progressive chronic disease without 
the need for foreign chemicals to induce inflammation. Using this 
model, it was shown that AIEC is resistant to innate antimicrobial 
defenses at the epithelial surface, including resistance to antimi-
crobial peptides released by Paneth cells and colonocytes (71). 
The molecular mechanism for this resistance involves, in part, the 
expression of a surface-localized protease that cleaves cationic host 
defense peptides to render them inactive. In addition to resistance 
to host-derived antimicrobial molecules, AIEC tend to be resist-
ant to multiple xenobiotic antimicrobials, particularly in isolates 
obtained from patients with ileal disease (72). This likely reflects 
the selective environment in which AIEC evolve within hosts, as 
CD patients are often given antibiotics as part of their treatment 
regimen. As of yet, no studies have examined whether eradicating 
AIEC is a viable or efficacious strategy in the treatment of CD; 
however, animal models permitting chronic colonization and 
disease progression will help facilitate such studies in the future.
CONCLUSiON
Intestinal bacteria play an important role in the pathogenesis of CD 
in a manner that is incompletely understood. External risk factors, 
such as acute infectious gastroenteritis and antibiotic exposure, are 
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moderately associated with CD, yet neither can be considered suf-
ficient to elicit disease on their own. It is likely that a combination of 
genetic and environmental risk factors is necessary in the pathogen-
esis of CD; however, exactly how such a constellation of risk factors 
manifest in disease expression has been a challenging problem to 
address. The study of mucosal-associated E. coli with pathobiont-like 
properties has yielded promising new leads into the pathogenesis 
of CD but more work needs to be done to understand where such 
microbes come from, where they evolve their pathogenic features, 
and what the effect of their eradication might have on susceptible 
hosts. A mechanistic understanding of the pathogenic microbes in 
CD will offer more therapeutic targets and perhaps paradigm shift-
ing approaches toward curative treatments for this disease.
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